

opl*: a zinc finger protein that regulates neural determination and patterning in *Xenopus

John S. Kuo^{2,*}, Mukesh Patel^{1,*}, Joshua Gamse¹, Christa Merzdorf¹, Xuedong Liu¹, Vladimir Apekin¹ and Hazel Sive^{1,†}

¹Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Nine Cambridge Center, Cambridge MA 02142, USA

²Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts, USA

*Equal contribution by two first authors

†Author for correspondence (e-mail: sive@wi.mit.edu)

Accepted 22 May; published on WWW 9 July 1998

SUMMARY

In order to study the mechanism of neural patterning in *Xenopus*, we used subtractive cloning to isolate genes activated early during this process. One gene isolated was *opl*, (*odd-paired-like*) that resembles the *Drosophila* pair-rule gene *odd-paired* and encodes a zinc finger protein that is a member of the *Zic* gene family. At the onset of gastrulation, *opl* is expressed throughout the presumptive neural plate, indicating that neural determination has begun at this stage while, by neurula, *opl* expression is restricted to the dorsal neural tube and neural crest. *opl* encodes a transcriptional activator, with a carboxy terminal regulatory domain, which when removed increases *opl* activity. *opl* both sensitizes animal cap ectoderm to the neural inducer *noggin* and alters the spectrum of genes induced by *noggin*, allowing activation

of the midbrain marker *engrailed*. Consistent with the later dorsal neural expression of *opl*, the activated form of *opl* is able to induce neural crest and dorsal neural tube markers both in animal caps and whole embryos. In ventral ectoderm, *opl* induces formation of loose cell aggregates that may indicate neural crest precursor cells. Aggregates do not express an epidermal marker, indicating that *opl* suppresses ventral fates. Together, these data suggest that *opl* may mediate neural competence and may be involved in activation of midbrain, dorsal neural and neural crest fates.

Key words: Subtractive cloning, Zinc finger, *odd-paired*, *Zic*, Competence, *engrailed*, Dorsal neural, Neural crest, *Xenopus*

INTRODUCTION

One of the first decisions made during neural determination in *Xenopus* is a general increase in the competence of the ectoderm to respond to subsequent neuralizing signals. Both transplantation experiments and exposure of explants to pure factors or to natural inducing tissue have shown that neural competence in *Xenopus* is maximal at early gastrula; by the end of gastrulation, ectoderm displays little competence to form neural tissue in response to mesoderm-derived signals (Nieuwkoop and Koster, 1995; Jones and Woodland, 1987; Sive et al., 1989; Servetnick and Grainger, 1991; Kintner and Dodd, 1991; Lamb et al., 1993; Knecht and Harland, 1997).

Superimposed on an increase in neural competence of the entire ectoderm is an enhanced competence of the dorsal ectoderm (the presumptive neurectoderm) for dorsal fates. The dorsal ectoderm is already biased towards dorsal fates by early blastula stages, since isolated dorsal ectoderm treated with activin goes on to form more dorsal mesoderm than does ventral ectoderm (Sokol and Melton, 1991). By early gastrula, isolated dorsal ectoderm fails to activate expression of the

epidermal antigen, Epi-1, whereas this antigen is strongly specified in the ventral ectoderm, which gives rise to epidermis (Savage and Phillips, 1989). Consistently, the dorsal ectoderm is more responsive than ventral ectoderm to neural-inducing signals arising from the dorsal mesendoderm (Sharpe et al., 1987).

By midgastrula, specification assays indicate that neural determination has occurred (Sive et al., 1989; Sharpe and Gurdon, 1990). Initial neural induction is thought to be anterior in character and appears to be mediated by antagonists of Bone Morphogenetic Proteins (BMPs), such as the secreted factors *noggin* and *chordin* (Eyal-Giladi, 1954; Sive et al., 1989; reviewed in Sasai and DeRobertis, 1997). Later, the posterior part of the neural plate is converted into posterior neural tissue. Retinoids, fibroblast growth factor and wnt proteins may all be involved in this process, perhaps acting at different anteroposterior levels (reviewed in Kolm and Sive, 1997).

Initiation of dorsoventral neural tube patterning also occurs during gastrulation (reviewed in Placzek and Furley, 1996). In *Xenopus* ventral parts of the neural tube have been specified by midgastrula (Saha et al., 1997) presumably under direction of

ventral midline-derived signals, particularly sonic hedgehog (Roelink et al., 1994). Similarly, at this time, expression of *pax3* (a dorsal neural tube marker) is beginning to be restricted to the future dorsal neural plate showing that dorsal neural fates have started to be determined (Bang et al., 1997). Final dorsal neural tube fates require input from adjacent non-neural ectoderm (Liem et al., 1995; Bang et al., 1997), including members of the TGF β gene family. The neural crest is specified later than dorsal neural tube, by the end of gastrulation, with specification increasing as the neural tube closes (Mayor et al., 1995). Neural crest induction requires signals both from the neural plate and from the juxtaposed non-neural ectoderm, and perhaps also signals from underlying paraxial mesoderm (reviewed in Bronner-Fraser, 1995).

Neural differentiation is regulated by genes such as *neurogenin*, *Xash3* and other members of the bHLH class (Turner and Weintraub, 1994; Zimmerman et al., 1993; Ma et al., 1996). Interfacing with neural differentiation is the correct patterning of the nervous system that must be controlled within the neuroectoderm by a distinct set of genes. However, few genes that control early patterning decisions within the neuroectoderm have been defined (for examples see Blitz and Cho, 1995; Pannese et al., 1995; Kolm and Sive, 1995a). In order to address this deficit, we have used subtractive cloning (Sagerström et al., 1997) to identify genes expressed specifically in the dorsal ectoderm during gastrula stages, after neural determination has occurred, but before neural differentiation has begun. To date, we have isolated more than 40 genes expressed preferentially in the dorsal ectoderm by midgastrula (Patel and Sive, 1996; Gamse, J., Kuo, J. S., Patel, M. and Sive, H., unpublished data). One of the earliest markers of the neuroectoderm that we identified is a zinc finger gene that is similar to *Drosophila odd-paired* (*opa*) (Benedyk et al., 1994) that we called *opl* for *odd-paired-like*. *opl* is a member of the *Zic* gene family, which comprises at least four members (Aruga et al., 1996).

Here we analyse the expression and activity of the *opl* gene. We show that *opl* expression demarcates the presumptive neural plate very early, by the onset of gastrulation, and later defines the dorsal neural tube and neural crest. *opl* can sensitize the neuroectoderm for induction, suggesting that *opl* may regulate neural competence. *opl* is also able to potentiate expression of a midbrain marker, as well as dorsal neural and neural crest marker genes, delineating a role in neural tube patterning for this gene.

MATERIALS AND METHODS

Growth, dissection and culture of embryos and explants

Xenopus laevis eggs were collected, fertilized and cultured as described in Sive et al. (1989). Embryos were staged according to Nieuwkoop and Faber (1967). For animal caps, late blastula (stage 9) animal hemisphere ectoderm was isolated and incubated in 0.5 \times MBS alone, or with other reagents as indicated. Dexamethasone (dex), and hydroxyurea and aphidicolin treatments were as described in Kolm and Sive (1995b) and Harris and Hartenstein (1991), respectively.

Subtractive cloning of *opl*

PCR-based subtractive cloning modified from Wang and Brown (1991) and described in detail by Patel and Sive (1996) was used to identify *opl*. RNA was isolated from dissected midgastrula (stage

11.5) dorsal ectoderm and blastula (stage 9-9.5) animal caps aged to midgastrula equivalent (stage 11.5) (Condie and Harland, 1987). cDNA was prepared by using the Pharmacia Timesaver cDNA synthesis kit. cDNA products were digested with *AluI* and *RsaI*, then ligated with oligo adaptors. Oligo 1 (5'-TAGTCCGAATTCAAGCAAGAGCACA-3') was kinased, annealed to oligo 2 (5'-CTCTTGCTTGAATTCGGACTA-3'), and ligated to the dorsal ectoderm (D) cDNA, thereby introducing flanking *EcoRI* sites (underlined). Oligo 3 (5'-ATGCTGGATATCTTGGTACTCTTCA-3') was kinased and annealed to oligo 4 (5'-GAGTACCAAGATATCCAGCAT-3'), and ligated to the animal cap (uninduced) ectoderm (U) cDNA, thereby introducing flanking *EcoRV* sites (underlined). Before each round of subtraction, tracer cDNA (from the D population) was PCR-amplified in the presence of ³²P-dCTP, and driver cDNA (from the U population) was PCR-amplified in the presence of biotinylated-11-dUTP (Enzo Diagnostics). Subtractive hybridization was carried out at 68°C, with long hybridizations (40 hours) alternating with short hybridizations (2 hours) to remove rare common sequences and abundant common sequences, respectively. Biotinylated duplexes were removed by treatment with streptavidin and phenol extraction, and enriched tracer and driver cDNAs were amplified for the next round of subtraction. 10 rounds of subtraction were performed to produce D₁₀ and U₁₀ cDNAs. D₁₀ cDNA products with average size of 300 bp (range 150 to 1000 bp) were cut with *EcoRI* and subcloned into CS2+ vector (Rupp et al., 1994). 800 clones were randomly selected and screened by dot blot analysis with probe prepared from D₁₀ and U₁₀ cDNAs to identify cDNAs expressed more strongly in the dorsal pool. 194 dorsal clones were sequenced and grouped into 75 sequence classes. 44 were of these were detected by in situ hybridization in gastrula stage dorsal ectoderm but not in ventral ectoderm. One of the most abundant clones isolated encoded *opl* (Fig. 1). A full-length *opl* cDNA clone was isolated from a midgastrula (stage 11.5) λ Zap phage library (prepared by C. Nocente-McGrath). Two cDNA clones were identified, the larger one (TG6.11) contained a 2.6 kb insert.

opl constructs

Constructs are diagrammed in Fig. 3. All techniques are as described in Sambrook et al. (1989), unless otherwise indicated. Enzymes were obtained from Stratagene or New England Biolabs. All constructs are in pCS2+ or pCS2+MT vectors (Rupp et al., 1994; Turner and Weintraub, 1994). The *opl* plasmid contained the *opl* open reading frame (ORF) fragment (699 bp) modified to include an optimal translation initiation site (Kozak, 1987) upstream of the *opl* initiation ATG and results in two extra amino acids (M-A) at the NH₂-end of translated peptide. To create *opl* Δ C, a *PstI* (end-filled)-*XhoI* (blunted) *opl* plasmid backbone was treated with Klenow fragment to remove 16 extra bp distal to the *XhoI* site (see Fig. 1) and then self-ligated. Myc-tagged *opl* (*MTopl*) was made by ligating an end-filled *EcoRI*-*XbaI* fragment into the *XbaI* (end-filled) site of CS2+MT. *MTopl* Δ C was made by ligating a *NotI*-*NotI* *opl* Δ C fragment into the *NotI*-digested *MTopl* vector backbone. To make constructs encoding inducible *opl* proteins (*oplGR*), the ligand-binding domain of the human glucocorticoid receptor was PCR-amplified from the *MyoDGR* plasmid (Hollenberg et al., 1993) with the primers MP-GR1-*XhoI* (5'-GGCGCCGAGCTCGAGCCTCTGAAAATCCT-3') and MP-GR2-*XhoI* (5'-GGCGGGCACTCGAGACTTTTGATGAAAC-3'). Products were then digested with *XhoI* (underlined) and inserted into an *XhoI*-digested *opl* plasmid.

Microinjection

Microinjection techniques were as described (Kolm and Sive, 1995a). 200 to 500 pg of *opl*, *opl* Δ C or *oplGR* RNAs were injected per embryo. 0.1 to 10 pg *noggin* RNA (derived from the CS2+*noggin* plasmid) per embryo was co-injected in the *opl* plus *noggin* synergy experiments. 100 pg *lacZ* RNA was co-injected as tracer in whole-embryo assays.

In vitro transcription

Capped sense RNAs for microinjection were synthesized as in Krieg and Melton (1984) and *lacZ* sense RNA as in Gammill and Sive (1997). All *opl*-derived sense RNAs (*opl*, *oplΔC*, *oplGR*, MT*opl*, MT*oplΔC*) were made by SP6 transcription of a *NarI-NarI* fragment from CS2+derived vectors. Other templates for sense RNAs are: *CAT* (p64TCAT; Kuo et al., 1996), *SmaI* linearized, SP6 transcribed; *globin* (pXβM), *PstI* linearized, SP6 transcribed; *noggin* (pCS2+*xnoggin*), *NotI* linearized, SP6 transcribed. Antisense probes for in situ hybridization were transcribed in the presence of digoxigenin-11-UTP or fluorescein-11-UTP as follows: *XCG* (Sive et al., 1989), *otx2* (Pannese et al., 1995), *en2* (Hemmati-Brivanlou and Harland, 1989), *krox20* (Bradley et al., 1993), *slug* (Mayor et al., 1995), *pax3* (Espeseth et al., 1995) and *XK81* (Jonas et al., 1985).

In situ hybridization and sectioning

Whole-mount in situ hybridization was performed on albino embryos essentially as described in Harland (1991) with modifications as in Sagerstrom et al. (1996). β-galactosidase staining was performed as in Kolm and Sive (1995a). For sections, embryos were embedded in JB4 resin (Polysciences 00226) and 5 to 10 μm sections were mounted in Crystal mount (Biomedica M03). Sections were stained with toluidine blue.

Isolation of RNA and northern analysis

RNA was prepared from explants and embryos by proteinase-K treatment and phenol extraction (Condie and Harland, 1987). RNA was analyzed by northern blotting (Sambrook et al., 1989). *opl* antisense probe was made by asymmetric PCR (Sive and Cheng, 1991) with the *opl*-D2 primer (5'-GTTGGCCAACTGCTCGG-3').

Relative quantitative RT-PCR

RNA from pools of 15-30 explants or 2-4 embryos was analysed by RT-PCR as described in Sagerström et al. (1996), using RNA from 5 animal cap equivalents or 0.25 embryo equivalents per reaction. *NCAM*, *en2*, *krox20* primers are described in Hemmati-Brivanlou and Melton (1994a). *EF1α* and *XCG* primers are described in Gammill and Sive (1997). Other primers yielding product sizes as indicated are: *otx2* – 485 bp [*Xotx2.C* (5'-GCAACAGCAGCAGCAGAATG-3'), *Xotx2.D* (5'-TGTAATCCAGGCAGTCAGTG-3')] (Pannese et al., 1995); *HoxD1* – 245 bp [*PJK3* (5'-CAGCCCGATTACGATTATTATGG-3'), *PJK4* (5'-CCGGGGAGGCAGGTTTTG-3')] (Kolm and Sive, 1995a); *HoxB9* – 201 bp [*HLS51* (5'-GCCCCTGCGCAATCTGAAC-3'), *HLS52* (5'-CAGCAGCGGCTCAGTCTGAG-3')] (Wright et al., 1990); *slug* – 220 bp [*Xslug1* (5'-GGTTCGATTTGCAGTATGG-3'), *Xslug2* (5'-GAGCTGCTTCGTAAAGCAC-3')] (Mayor et al., 1995); *pax3* – 181 bp [*pax3A* (5'-CAGCCGAATTTGAGGAGCACAT-3'), *pax3B* (5'-GGGCAGGTCTGGTTCGGAGTC-3')] (Espeseth et al., 1995); *NK2* – 406 bp [*NK2.1* (5'-AGAAACCGTCCGCTGATGAGTC-3'), *NK2.2* (5'-TGGGCGCTATAGGCAGAGAAAG-3')] (Saha et al., 1993); *shh* – 191 bp [*shh1* (5'-GGTTGACCCGCGCCCATCTAC-3'), *shh2* (5'-AGGCGATAAGCTCCAGTGTC-3')] (Ekker et al., 1995); *Xash3* – 227 bp [forward (5'-AAGCGCTCCTGTCAAACACTAT-3'), reverse (5'-CCCCGCGCTCCTCTCC-3')] (Zimmerman et al., 1993); *neurogenin* – 263 bp [forward (5'-CGCCGAACCCGACTACCT-3'), reverse (5'-CCTGCATCGCGGGTCTTCTC-3')] (Ma et al., 1996); *XK81* – 308 bp [forward (5'-TCATTCCGTTCCAGCTTCTTAC-3'), reverse (5'-TCCAGGGCTCTTACTTTCTCCAG-3')] (Jonas et al., 1985); *GATA2* – 415 bp [forward (5'-CTAAACAGAGGAGCAAGAGC-3'), reverse (5'-CCTGGAAAGTTCTCAAAC-3')] (Walmsley et al., 1994); *m-actin* – 222 bp [forward (5'-GCTGACAGAATGCAGAAG-3'), reverse (5'-TTGCTTGGAGGAGTGTGT-3')] (Stutz and Spohr, 1986).

Western analysis and immunocytochemistry

Western blotting (Kolm and Sive, 1995b) and whole-mount

immunostaining (Hemmati-Brivanlou and Harland, 1989) were performed using the c-myc 9E10 antibody (Santa Cruz Biotechnology) diluted 1:1000 (0.1 μg/ml) and the ECL Vector Elite kit from Amersham.

Transient transfection reporter assays

A reporter plasmid (pGL15) containing three Gli3 DNA-binding sites (Vortkamp et al., 1995) and a luciferase reporter was mixed with CS2+ or CS2+*opl* ORF or CS2+*oplΔC* plasmids for transfections at the ratio of 5 μg:1 μg. The human pancreatic tumor cell line BXPC (ATCC #CRL 1687) were transfected using the DEAE-dextran/chloroquine method (Aruffo and Seed, 1987), and cell lysates were assayed 48 hours after transfection for luciferase activity using the Promega Luciferase Assay System (E1501) on a Analytical Luminescence Laboratory Monolight 2010 machine. Duplicate transfections were done for each DNA mix and duplicate readings were taken for each lysate sample.

RESULTS

opl encodes a zinc finger protein with similarity to the Zic family

In order to isolate genes activated soon after neural determination has begun in *Xenopus*, we subtracted cDNAs from microdissected midgastrula dorsal ectoderm with those from uninduced ectoderm aged until midgastrula (Patel and Sive, 1996). One of the genes that we isolated encodes a 443 amino acid protein with five zinc fingers of the C2H2 class (GenBank accession no. AF028805). By comparison with invertebrate zinc finger genes, the zinc fingers of this gene were most similar (85%) to those of the *Drosophila odd-paired* gene (*opa*), a pair-rule gene (Benedyk et al., 1994), and we therefore named this gene *opl* for *odd-paired*-like. Among the vertebrate zinc finger genes, the zinc fingers of *opl* were similar to those of the *Gli* family genes (53% identity to the zinc fingers of human *Gli3* (Ruppert et al., 1988)), but even more similar to the family of mouse *Zic* genes. The *Zic* genes share intron/exon boundaries with *Drosophila odd-paired* (Aruga et al., 1996) indicating that these are true homologs of *opa* (Fig. 1A). Over the entire coding region, *opl* was very similar to mouse *Zic1*, with 91% overall amino acid identity (Fig. 1B, (Aruga et al., 1994)). It was much less similar to the proteins encoded by other members of the *Zic* gene family, with 63% identity to mouse *Zic2*, 60% identity to *Zic3* and 54% identity to *Zic4* (Aruga et al., 1996). Recent reports describing isolation of *Xenopus Zic* members include *Zic3* (Nakata et al., 1997), which has 60% identity to *opl*, while the percentage identity of *opl* and *Zic-r1* (Mizuseki et al., 1998) is not clear. On the basis of these data, *opl* may be the *Xenopus* homolog of *Zic1*. However, since we cannot conclude this unequivocally and in order to reflect the similarity of this gene to *Drosophila opa*, we chose the name *opl*.

Temporal and spatial characterization of opl expression

We next examined the time course of *opl* expression by northern analysis (Fig. 2). *opl* RNA is activated zygotically by late blastula (stage 9.5, lane 3). Expression was maximal by midgastrula (lanes 4-7), with lower expression persisting into tailbud stages (lanes 8-11).

By whole-mount in situ hybridization, *opl* expression was




Fig. 2. (A) Northern analysis of *Xenopus* embryos. One embryo equivalent per lane was analyzed for *opl* RNA (top row) at various embryonic stages shown. Ethidium-stained 28S rRNA is a loading control (bottom row).

posterior hyoid and branchial neural crest (Sadaghiani and Thiebaud, 1987). By tailbud, expression was high in two stripes located in the telencephalon and diencephalon of the forebrain, and more posteriorly along the entire length of the neural tube (Fig. 3I,J).

In order to analyse *opl* expression in more detail, embryos stained for *opl* RNA were sectioned sagittally. At stage 10+ (the onset of gastrulation), *opl* expression was observed in both the inner and outer layers of the dorsal ectoderm (Fig. 4A,B) in a region largely without underlying mesendoderm (bracket). By midgastrula (stage 11) (Fig. 4C,D) and late gastrula (Fig. 4E), *opl* expression was excluded from the extreme posterior neurectoderm. Sequential transverse sections of a tailbud embryo showed that, within the spinal cord, *opl* expression was restricted to the roof plate of the neural tube (Fig. 4F, black arrow) and the migratory neural crest (Fig. 4F, white arrow). In the hindbrain, *opl* expression extended into the more ventral alar plate region of the neural tube (Fig. 4G,H). At the midbrain level, *opl* expression extended through the dorsal half of the neural tube (Fig. 4I), while more anteriorly, in the forebrain, *opl* expression was lost from roof plate and retained in the alar plate (Fig. 4J).

In order to delineate the expression of *opl* relative to other positions in the neural tube, we performed comparative in situ hybridization with other dorsal ectodermal markers (Fig. 5). At midneurula, expression of the forebrain and cement gland marker *otx2* (Blitz and Cho, 1995; Pannese et al., 1995) overlapped with that of *opl* anteriorly, extending to the anterior boundary of the neural plate, but *opl* is excluded from the dorsal medial region and the future cement gland (bracket) (Fig. 5A). Consistently, *opl* was expressed more posteriorly than *XCG*, a marker of the cement gland (Sive et al., 1989) that lies anterior to the neural plate (Fig. 5B). Expression of *slug* (Mayor et al., 1995) in the premigratory cranial neural crest overlapped that of *opl*, confirming that *opl* expression extended beyond the edges of the neural plate (Fig. 5C). Relative to

engrailed 2 (*en2*) at the midbrain/hindbrain junction (Hemmati-Briuanlou and Harland, 1989) and *krox20*, demarcating future rhombomeres 3 and 5 of the hindbrain (Bradley et al., 1993), *opl* expression at early neurula extends posterior to the rhombomere 5 stripe of *krox20* (Fig. 5D).

In summary, *opl* expression is an early marker of the presumptive neurectoderm with later expression marking the dorsal neural tube and neural crest. Recent analyses of the *Xenopus Zic3* (Nakata et al., 1997) and a *Zic1*-related gene (*Zic-r1*) (Mizuseki et al., 1998) indicate that the expression patterns of these genes and *opl* are similar.

***opl* is a nuclear protein whose carboxy terminal encodes a regulatory domain**

We next characterized the activity and localization of the *opl* protein. Since mouse *Zic1* is a nuclear protein that can bind the DNA target site of the related zinc finger protein *Gli3* (Fig. 1A; Aruga et al., 1994), we assumed that *opl* was a transcription factor and asked whether it had activator or repressor functions. The carboxy terminus of *opl* is highly serine-rich, suggesting it may be a phosphorylation domain (see Fig. 1B). We removed this region (to create *oplΔC*) and asked whether it played a regulatory role in *opl* activity, using a reporter assay. The various constructs used are diagrammed in Fig. 6 and described in Methods. The reporter consisted of *luciferase* linked to three copies of the *Gli3* consensus DNA-binding site (Fig. 7A; (Vortkamp et al., 1995). The activity of intact *opl* or *oplΔC* was assayed in transient transfection assays (see Methods). The averaged results of three experiments are shown in Fig. 7A. While *opl* was able to activate reporter gene expression 2.8-fold above background, *oplΔC* was able to activate reporter gene expression 14.6-fold above background, indicating that this mutant allele of *opl* has an enhanced transcriptional activation capacity and designating the carboxy terminus of *opl* as a domain that is able to suppress *opl* activity. This transactivation requires *Gli3*-binding sites, since a reporter lacking these sites (containing an SV40 promoter) was not activated above background levels by either *opl* or *oplΔC* (not shown).

We also asked whether the *opl* protein was localized to the nucleus and whether C-terminal removal altered its




Fig. 3. Whole-mount in situ analysis of *opl* expression. Embryos were analyzed by in situ hybridization as described in Methods. Embryo orientations are indicated by A, anterior; P, posterior; D, dorsal and V, ventral; arrowhead, dorsal lip of blastopore.




Fig. 4. Sections of embryos analyzed by whole-mount in situ hybridization for *opl* expression. Embryos were fixed, embedded and sectioned as described in Methods. Sectioning planes are shown in schematic diagrams above panels. Black arrowheads indicate position of dorsal blastopore lip. Black arrows indicate *opl* expression in roofplate. White arrows indicate spinal crest expression. Brackets indicate alar plate expression in forebrain/midbrain regions. D, dorsal; V, ventral. Scale bar, 25 μ m.

nucleocytoplasmic distribution, using myc-epitope tagged versions of both *opl* and *opl* Δ C, MT-*opl* and MT-*opl* Δ C (see Methods). One cell of a 2-cell embryo was injected with RNA encoding either of these constructs and examined at midgastrula for distribution of the epitope-tagged *opl* using whole-mount immunocytochemistry. As shown in Fig. 7B, both the intact (MT-*opl*) and carboxy terminal truncated (MT-*opl* Δ C) proteins were nuclear, with no obvious differences in the distribution of either construct. We were also unable to detect any differences in the amount of *opl* protein produced in embryos from either MT-*opl* or MT-*opl* Δ C (not shown).

In summary, this analysis suggested that *opl* is a transcriptional activator and defined a putative regulatory domain in the carboxy region of the *opl* protein. This region repressed the ability of *opl* to act as an activator but had no effect on the nucleocytoplasmic distribution of *opl*.

***opl* Δ C activates neural crest and dorsal neural tube markers**

The neuroectodermal restriction of *opl* expression suggested that it may play a role in neural determination. We tested this possibility in an animal cap assay. RNA encoding *opl*, *opl* Δ C or CAT (as control) was injected into the animal pole region of two cell embryos. At late blastula (stage 9), animal caps were removed, cultured until tailbud (stage 22) and marker gene expression was analysed using a reverse transcriptase-polymerase chain reaction (RT-PCR) assay (Fig. 8A and Methods).

One of three representative experiments is shown in Fig. 8B. After injection of CAT RNA, we observed only background levels of the neural-specific markers *Xash3* (Zimmerman et al., 1993), *neurogenin* (Ma et al., 1996), *NCAM* (Kintner and Melton, 1987),

the neural crest marker *slug* (Mayor et al., 1995), the dorsal neural tube marker *pax3* (Espeseth et al., 1995) and the ventral neural tube marker Sonic hedgehog (*shh*) (Ekker et al., 1995) (Fig. 5B, lane 2). In contrast, high levels of the ventral ectodermal markers *XK81* (Jonas et al., 1985) and *GATA2* (Walmsley et al., 1994) were observed after this treatment (lane 2). Injection of *opl* or *opl* Δ C RNAs did not induce expression of *NCAM*, *Xash3* or *neurogenin* (lanes 3 and 4), however *opl* Δ C (lane 3), but not *opl*




Fig. 5. Double whole-mount in situ analysis of *opl*. In situ analysis was as described in Methods with *opl* stained light blue and all other markers (*otx-2*, *XCG*, *slug*, *en-2*, *kroxx20*) are stained purple. (A) *opl* plus *otx-2*, a marker of forebrain and cement gland (Blitz and Cho, 1995; Pannese et al., 1995), bracket shows *otx-2* expression in cement gland primordium; (B) *opl* plus *XCG*, a cement gland marker (Sive et al., 1989), bracket shows *XCG* expression in cement gland; (C) *opl* plus *slug*, a neural crest marker (Mayor et al., 1995), bracket shows *slug* domain contained within *opl* domain; (D) *opl* plus *en-2*, a marker of the midbrain/hindbrain regions (Hemmati-Brivanlou and Harland, 1989) and *kroxx20*, a marker of presumptive rhombomeres 3 and 5 in the hindbrain (Bradley et al., 1993). White arrowhead indicates *en-2* expression, black arrowheads indicate *kroxx20* expression, white bar is posterior limit of early *opl* expression.




Fig. 6. *opl* constructs. The *opl* construct comprises the coding region of *opl*; *opl*Δ*C* deletes a serine-rich carboxy terminal domain (S), *opl*GR comprises an in-frame fusion of the *opl*-coding sequence with the hormone-binding domain of the glucocorticoid receptor (Kolm and Sive, 1995b). MT-*opl* is an in-frame fusion of the *opl*-coding region with a multimerized myc epitope (MT, black circle) at the amino end of *opl* (Rupp et al., 1994) and MT-*opl*Δ*C* is a similar fusion of the multimerized myc epitope with the carboxy deleted *opl*. See Methods for details.

(lane 4) was able to activate expression of *slug* (4-fold over *CAT*-injected levels, averaged over three experiments) and *pax3* (3.5-fold over *CAT*-injected levels). *shh* was not activated by injection of either construct. We also asked whether *opl* or *opl*Δ*C* could suppress non-neural ectodermal differentiation, by assaying the expression of *XK81* and *GATA2* as ventral markers. Both *opl* and *opl*Δ*C* were able to suppress expression of *XK81* by 2-fold relative to *CAT*-injected samples. Additionally, while *opl*Δ*C* was unable to suppress *GATA2* expression, *opl* consistently suppressed expression of *GATA2* by 2-fold.

In summary, these data showed that neither *opl* nor its activated form, *opl*Δ*C*, could activate expression of neural-specific genes in uninduced ectoderm. However, consistent with the later expression pattern of *opl* in the dorsal neural tube, *opl*Δ*C* efficiently induced expression of neural crest and dorsal neural tube markers. These data contrast with those obtained after injection of *Zic3* and *Zic-rl* RNAs, where multiple neural-specific markers as well as *slug* were activated (Nakata et al., 1997; Mizuseki et al., 1998). It is not clear whether this represents a difference in the experimental conditions used, or a difference in the activities of *opl* and these related genes.

***opl*Δ*C* sensitizes the ectoderm to induction by noggin**

The early expression domain of *opl* in the dorsal ectoderm correlated with the region of the gastrula ectoderm that is most competent to respond to neural induction. We therefore asked whether *opl* could act as a modulator of neural competence and sensitize ectoderm to the neural-inducing activity of noggin, a factor that acts by antagonizing BMP signaling (Lamb et al., 1993), using the animal cap assay diagrammed in Fig. 8A. Embryos were injected with varying amounts of *noggin* RNA alone or together with *opl*Δ*C* RNA or with *globin* RNA as a control and caps later analysed by RT-PCR for expression of two neural-specific genes, *NCAM* and *Xash3*.

A representative experiment (of three) is shown in Fig. 9.




Fig. 7. *opl* is a nuclear protein with a regulatory domain in the COOH-terminal. (A) *opl* protein transactivates reporter constructs in tissue culture. Transient transfection reporter assays were performed as described in Methods, using the human pancreatic tumor BXPC cell line. The reporter construct is shown schematically: three Gli3 DNA-binding sites are located 5' to a basal promoter (TATA box) and *luciferase* reporter gene (Vortkamp et al., 1995) Data shown are the averages of three independent experiments with corresponding error bars. In the absence of the Gli3-binding sites, neither *opl* nor *opl*Δ*C* activated a reporter construct (not shown). DNA mixes for transient transfections are as follows, Left panel, reporter plus CS2+vector; middle panel, reporter plus CS2+*opl* ORF right panel, reporter plus pCS2-*opl*Δ*C*. (B) Immunocytochemistry of injected *opl* and *opl*Δ*C* proteins. Albino embryos were injected with 500 pg of synthetic MT*opl* or MT*opl*Δ*C* RNA at 2- to 4-cell stages and analyzed at stage 11 by immunostaining with anti-myc 9E10 antibody as described in Methods. Views of the animal hemispheres are shown, left panel, MT*opl*-injected embryo, right panel, MT*opl*Δ*C*-injected embryo.

Neither *globin* RNA (lane 1) nor *opl*Δ*C* alone (lane 2) induced *NCAM* or *Xash3* RNA expression, consistent with results shown in Fig. 8. 0.1 pg *noggin* RNA did not induce either *NCAM* or *Xash3* (lane 3) and 1 pg *noggin* RNA did not induce *NCAM* and activated *Xash3* only weakly (lane 4). 10 pg *noggin* RNA strongly activated both *NCAM* and *Xash3* expression (lane 5). At 0.1 pg *noggin* RNA plus *opl*Δ*C* RNA, no *NCAM* and very weak *Xash3* expression was observed (lane 6); however, at 1 pg *noggin* RNA plus *opl*Δ*C*, strong expression of both *NCAM* and *Xash3* was observed (lane 7), to levels that were almost as strong as seen with 10 pg of *noggin* alone. At higher *noggin* concentration (10 pg) plus *opl*Δ*C*, no further potentiation of *NCAM* and *Xash3* was observed (lane 8) and, in the experiment shown, *Xash3* RNA accumulation declined relative to 1 pg *noggin* plus *opl*Δ*C*, perhaps indicating that saturation of the induction machinery had occurred.

In summary, these data showed that *opl*Δ*C* could sensitize isolated ectoderm to the neural-inducing effects of *noggin*, indicating that *opl* can regulate neural induction, and consistent with a role for *opl* in mediating neural competence.




Fig. 8. *oplΔC* can activate neural crest and dorsal neural tube marker genes in animal caps. (A) Experimental scheme. Wild-type embryos were injected in both blastomeres with 200 pg of indicated RNAs at the 2-cell stage. Injection of *CAT* RNA served as negative control by equalizing the injected RNA dose. Pools of 15–20 animal caps were isolated from injected embryos at late blastula (stage 9) and incubated in saline until harvest at tailbud (stage 22) for RT-PCR analysis. See Methods for details. (B) Expression of marker genes in animal caps. Uninjected embryos serve as control for baseline expression level. *Xash3* (Zimmerman et al., 1993), *neurogenin* (Ma et al., 1996) and *NCAM* (Kintner and Melton, 1987) are neural-specific markers; *slug* (Mayor et al., 1995) is a neural crest marker; *pax3* (Espeseth et al., 1995) marks the dorsal neural tube, *shh* marks the floorplate (Ekker et al., 1995); *XK81* (Jonas et al., 1985) and *GATA2* (Walmsley et al., 1994) are markers of the ventral ectoderm; *EF1α* (Krieg et al., 1989) served as loading control. Samples processed without RT did not show *EF1α* signal after PCR (not shown). Data from one representative experiment is shown; similar results were obtained from three experiments. Lane 1, stage 22 embryo; lane 2, *CAT*-injected animal caps; lane 3, *oplΔC*-injected caps; lane 4, *opl*-injected caps.

In conjunction with *noggin*, *opl* activates posterior and dorsoventral neural markers

Having shown that *oplΔC* could sensitize the ectoderm for responsiveness to *noggin*, we next asked whether *opl* or *oplΔC* could alter the spectrum of neural markers induced by high levels of *noggin* that were characteristic of particular anteroposterior or dorsoventral axial positions, using the animal cap assay diagrammed in Fig. 8A with *CAT* RNA as control. Expression levels of the general neural marker *NCAM*




Fig. 9. *oplΔC* sensitizes the ectoderm to induction by *noggin*. Wild-type embryos were injected in both blastomeres with indicated RNAs at the two-cell stage, using 200 pg *globin* or *oplΔC*, and 0.1 pg, 1 pg or 10 pg *noggin* (Smith and Harland, 1992) RNAs, as diagrammed in Fig. 8A, except injection of *globin* RNA served as negative control by equalizing the injected RNA dose in all lanes. Pools of 15–20 animal caps were isolated from injected embryos at late blastula (stage 9) and incubated in saline until harvest at tailbud (stage 22) for RT-PCR analysis. See Methods for details. Expression of neural markers *NCAM* (Kintner and Melton, 1987) and *Xash3* (Zimmerman et al., 1993) was analysed. *EF1α* served as loading control (Krieg et al., 1989). Samples processed without RT did not show *EF1α* signal after PCR (not shown). Data from one representative experiment is shown, similar results were obtained from three experiments. Lane 1, *globin*-injected caps; lane 2, caps injected with 200 pg *oplΔC* RNA; lane 3, caps injected with 0.1 pg *noggin* RNA; lane 4, caps injected with 1 pg *noggin* RNA; lane 5, caps injected with 10 pg *noggin* RNA; lane 6, caps injected with 0.1 pg *noggin* RNA plus 200 pg *oplΔC* RNA; lane 7, caps injected with 1 pg *noggin* RNA plus 200 pg *oplΔC* RNA; lane 8, caps injected with 10 pg *noggin* RNA plus 200 pg *oplΔC* RNA.

and marker genes differentially expressed along the anteroposterior (A/P) or dorsoventral (D/V) axes of the neural tube were assayed by RT-PCR.

One of four representative experiments is shown in Fig. 10. Uninjected caps (or caps injected with *CAT* RNAs (not shown)) failed to express all dorsal ectodermal and mesodermal markers examined (lane 2). Injection of *noggin* plus *CAT* RNAs (lane 3) led to activation of *NCAM*, the cement gland marker *XCG* (Sive et al., 1989) and the forebrain plus cement gland marker *otx2* (Blitz and Cho, 1995; Pannese et al., 1995), but activated only low levels of markers that were more posterior. Injection of *oplΔC* (lane 3) or intact *opl* (not shown) RNAs alone led to weak activation of the hindbrain markers *krox20* (Bradley et al., 1993), *HoxD1* (Kolm and Sive, 1995a) and less reproducibly, the spinal cord marker *HoxB9* (Wright et al., 1990), but failed to activate either *NCAM* or the anterior markers *XCG*, *otx2* and *en2* (Hemmati-Brivanlou and Harland, 1989). However, expression of *oplΔC* plus *noggin* (lane 5) or *opl* plus *noggin* (lane 6), reproducibly led to very strong activation of *en2*, expressed at the midbrain/hindbrain junction (25-fold for *oplΔC*, and 7-fold for *opl*, averaged over four experiments). *oplΔC* (but not *opl*) was also able to activate expression of *krox20* and *HoxD1*, (lane 5), with the extent of activation varying between experiments, while *HoxB9* expression was not reproducibly activated.

We also examined synergy of *opl* or *oplΔC* with *noggin* with respect to markers expressed along the D/V aspect of the neural tube. Injection of *noggin* RNA together with control *CAT* RNA (lane 3) induced low levels of the dorsal marker *pax3* (Espeseth

et al., 1995), the ventrolateral marker *NK2* (Saha et al., 1993) and the ventral marker *shh*. Consistent with the data shown in Fig. 8, *oplΔC* alone (lane 4) was very effective at activating expression of the neural crest markers *slug*, *twist* (Hopwood et al., 1989) (not shown) and *pax3*. In conjunction with *noggin*, *oplΔC* (lane 5) also activated expression of genes normally restricted to the ventrolateral and ventral neural tube including




Fig. 10. *opl* synergizes with *noggin* to activate more posterior neural markers in animal caps. Wild-type embryos were injected in both blastomeres with indicated RNAs at the 2-cell stage, using 200 pg *CAT*, *opl* or *oplΔC*, and 10 pg *noggin* (Smith and Harland, 1992) RNAs, as diagrammed in Fig. 8A. Injection of *CAT* RNA served as negative control by equalizing the injected RNA dose. Pools of 15-20 animal caps were isolated from injected embryos at late blastula (stage 9) and incubated in saline until harvest at tailbud (stage 22) for RT-PCR analysis. See Methods for details. Expression of a set of neural markers expressed along the anteroposterior (A/P) or dorsoventral (D/V) neural axes was analysed. Uninjected embryos serve as control for baseline expression level. *NCAM* is a general neural marker (Kintner and Melton, 1987). Expressed in the indicated anterior (A)-to-posterior (P) series: *XCG* is a cement gland marker, the most anterior ectodermal tissue (Sive et al., 1989); *otx-2* is a forebrain and cement gland marker (Blitz and Cho, 1995; Pannese et al., 1995); *en2* is a marker of mid/hindbrain boundary (Hemmati-Brivanlou and Harland, 1989); *krox20* marks rhombomeres 3 and 5 in the presumptive hindbrain (Bradley et al., 1993); *HoxD1* is a hindbrain (posterior to rhombomere 4) and spinal cord marker (Kolm and Sive, 1995a), and *HoxB9* is a spinal cord marker (Wright et al., 1990). Expressed in the indicated dorsal (D) to ventral (V) series of markers, *slug* (marking the neural crest, (Mayor et al., 1995)), *pax3* (marking the dorsal neural tube, (Espeseth et al., 1995)), *NK2* (marking the ventrolateral neural tube, (Saha et al., 1993)) and *shh* (marking the floorplate, (Ekker et al., 1995)). *M-actin* (Mohun et al., 1984) is a mesodermal marker; *EF1α* (Krieg et al., 1989) served as loading control. Samples processed without RT did not show *EF1α* signal after PCR (not shown). Data from one experiment are shown, comparable results were obtained in four independent experiments. Lane 1, stage 22 embryo; lane 2, uninjected animal caps; lane 3, *noggin* plus *CAT*-injected; lane 4, *oplΔC*-injected; lane 5, *noggin* plus *oplΔC*-injected; lane 6, *noggin* plus *opl*-injected.

NK2, *shh* and *F-spondin* (Ruiz i Altaba et al., 1995) (not shown). Intact *opl* protein in conjunction with *noggin* activated high levels of *pax3*, *NK2* and *shh*, but did not efficiently activate *slug* or *twist* (not shown) expression (lane 6). Expression of mesodermal genes, including muscle actin, was not activated by any of these injections.

Overall, this assay demonstrated that *opl* and *oplΔC* were able to alter the A/P and D/V spectrum of genes activated by *noggin*, suggesting that *opl* may act as a modulator of positional information along the A/P and D/V neural axes. As in the assay for transcriptional activation, *oplΔC* was more active than native *opl* protein.

***opl* induces cellular aggregates in the absence of DNA synthesis**

Since *opl* and *oplΔC* were able to alter neural marker gene




Fig. 11. *opl* induces cellular aggregates without cell division. (A) Experimental scheme. Wild-type embryos were injected in one cell at the 2-cell stage with 500 pg of *oplGR* or *oplΔC* RNA plus 100 pg *lacZ* RNA as lineage tracer. Injected embryos were incubated in saline alone or with dexamethasone (dex) and/or hydroxyurea (HUA) starting at early gastrula (stage 10) until late neurula (stage 19). See Methods for details. (B-H) Morphology and histology of *opl*-induced cellular aggregates. β-gal staining is obscured by pigment. (B-E) Anterior (A) is to the left, dorsal is to the top. (B) Embryo injected with *oplGR* RNA without dex addition; (C,D) embryos injected with *oplGR* RNA and treated with dex from stage 10 until harvest. Arrows point to cellular aggregates in ventrolateral ectoderm. (E) Embryo injected with *oplGR* RNA and treated with HUA plus dex from stage 10 until harvest. (F-H) Embryos sectioned and stained after *oplΔC* injection. (F) +dex, transverse section of stage 19 embryo through trunk region. Regions magnified in G and H are boxed and indicate uninjected and injected sides of the embryo respectively, as judged by β-gal staining. (G) Uninjected side; (H) injected side. The width of the ectoderm is bracketed in G and H. D, dorsal; V, ventral.

Table 1. Frequency of ectopic cellular aggregates in injected embryos

Treatment*	Ectopic aggregates (%)†	Number of embryos‡	Number of experiments§
<i>opl</i>	35 (15)	263	7
<i>oplΔC</i>	232 (64)	361	17
<i>oplΔC</i> +HUA	77 (57)	135	4
<i>oplGR</i>			
-dex	0 (0)	72	2
+dex	26 (50)	52	2
<i>oplGR</i>			
-HUA+dex	19 (66)	29	1
+HUA+dex	18 (58)	31	1
globin	0 (0)	244	12

Embryos were prepared as described in Fig. 11A; pigmented cellular aggregates were scored at stage 19.

*One blastomere of two-cell embryos was injected with *opl*, *oplΔC*, *oplGR* or globin RNAs. Embryos were incubated in saline or with 10 μM dexamethasone (dex) until harvest at stage 19. See Methods for details.

†Number and frequency of embryos showing pigmented cellular aggregates in the region of injected RNA (marked by βGal staining).

‡Total number of embryos examined.

§Number of independent experiments.

expression in animal cap assays, we wanted to determine whether ectopic *opl* expression could alter neurogenesis in the intact embryo. To do this, we compared the effects of native *opl* protein, *oplΔC*, and a hormone inducible version of *opl*, *oplGR*, on the morphology of whole embryos. *oplGR* comprises the *opl*-coding region linked in frame to the ligand-binding domain of the glucocorticoid receptor (GR). We have previously shown that such constructs are post-translationally hormone inducible in *Xenopus* embryos, and can be activated at the time when the endogenous gene is maximally expressed (Kolm and Sive, 1995b). Embryos were injected with RNA encoding either *oplGR*, along with *lacZ* RNA as a lineage tracer (Fig. 11A). *oplGR* constructs were activated by dexamethasone (dex) at early gastrula, and embryos later assayed morphologically.

The results of this analysis are shown in Fig. 11 and collated in Table 1. Without dex treatment embryos appeared normal (Fig. 11B), while after activation of the *oplGR* protein at early gastrula, large pigmented aggregates were seen in the ventral and lateral ectoderm (Fig. 11C,D) in 50% of all embryos. These aggregates were also observed after ectopic *opl* misexpression in 15% of embryos, and after ectopic *oplΔC* expression in 64% of embryos, consistent with the greater activity of *oplΔC* (Table 1). Aggregates were observed in the ectoderm and adjacent to the neural plate, but not within the neural plate itself. The increased activity of *oplGR* relative to *opl* in this assay is similar to that of *oplΔC* and is likely to be due to the presence of a weak activation domain in the GR, that can overcome the inhibitory domain of intact *opl* protein (Mattioni et al., 1994).

We next asked whether the aggregates observed after *opl* misexpression were a result of increased proliferation or cell aggregation. Embryos injected with *oplGR* were pretreated with hydroxyurea and aphidicolin (HUA) to inhibit DNA synthesis and cell division (Harris and Hartenstein, 1991), before dexamethasone treatment (Fig. 11A). After this treatment, cells remained large, consistent with the absence of

Table 2. Induction of cellular aggregates depends on time of addition and duration of dex treatment in *oplGR*-injected embryos

Stage of dex addition*	Stage of maximal phenotype (elapsed hours)†	Ectopic aggregates (%)‡	Number of embryos§	Number of experiments¶
8	15 (12.5)	19 (59)	32	2
10	15 (8)	28 (85)	33	2
11.5	14 (4.5)	20 (59)	34	2
12	20 (8)	22 (71)	31	2
15	24 (9)	14 (78)	18	1
18	25 (9)	3 (15)	20	2
24	36 (24)	0 (0)	10	1

Embryos were prepared as described in Fig. 8A; pigmented cellular aggregates were scored over time after addition of dexamethasone (dex).

*Stage when dex treatment was started.

†Stage and elapsed hours since start of dex treatment when maximal size and extent of pigmented cellular aggregates was observed in embryos.

‡Number and frequency of embryos with ectopic pigmented cellular aggregates.

§Total number of embryos examined.

¶Number of independent experiments.

cell division (not shown). As shown in Fig. 11E, cell aggregates were observed even in the absence of DNA synthesis in 58% of embryos, similar to the percentage observed without HUA treatment (66%; Table 1). Similar results were obtained after injection of *oplΔC* in the presence of HUA (Table 1).

A section of an embryo, injected with *oplGR* RNA and treated with dex at stage 10, formed a ventral aggregate (Fig. 11F). In close up, the uninjected side shows the three germ layers, including a tightly packed ectodermal epithelium (bracket, Fig. 11G). In contrast, on the injected side of the embryos the ectoderm was organized as a loosely packed mass of cells, which included pigmented cells not arranged in the characteristic epithelium seen in control embryos (Fig. 11H). The mesodermal and endodermal layers appeared morphologically normal.

Additionally, we asked when the embryo was competent to form aggregates. After injection of *oplGR* RNA followed by dex treatment at various times after injection (Fig. 11A), embryos were later scored for appearance of maximally sized aggregates. The results are collated in Table 2. After dex induction at midblastula (stage 8), embryos took 12.5 hours to form aggregates of maximal size, whereas by early gastrula (stage 10) only 8 hours elapsed before aggregate formation. By midgastrula (stage 11.5), only 4 hours elapsed after dex addition before maximal aggregate formation occurred and this was the shortest lag time observed. Older embryos (late gastrula (stage 12), early neurula (stage 15) and late neurula (stage 18) all formed aggregates, but at 8 to 9 hours after dex addition. No aggregates were observed after dex addition at tailbud (stage 24), but it was not clear whether this reflected a lack of competence to form aggregates or degradation of *oplGR* RNA.

In summary, *opl*, *oplΔC* and *oplGR* proteins were able to activate formation of large pigmented aggregates in the ventral and lateral ectoderm. These appeared to be loose associations of cells and were not caused by an increase in cell proliferation. Embryos were competent to form aggregates from midblastula

through late neurula, with the time of maximal competence at midgastrula.

***opl* activates expression of neural crest and dorsal neural tube markers and represses epidermal gene expression in whole embryos**

We extended the analysis in whole embryos to ask whether *opl* constructs can activate ectopic expression of neural crest

Table 3. Frequency of ectopic *slug* and *pax3* expression in *oplGR*-injected embryos

Treatment*	Marker examined†	Ectopic expression(%)‡	Number of embryos§	Number of experiments¶
<i>oplGR</i>	<i>slug</i>	1 (3)	35	3
-dex	<i>pax3</i>	0 (0)	38	4
+dex	<i>slug</i>	18 (42)	43	3
	<i>pax3</i>	58 (75)	77	4

Embryos were prepared as described in Fig. 8A; *slug* and *pax3* expression was scored by in situ hybridization on neurula (stage 18) embryos.

*One blastomere of 2-cell embryos was injected with *oplGR* RNA. Embryos were incubated in saline or with 10 mM dexamethasone (dex) starting at stage 11 until harvested at stage 18. See Methods for details.

†*slug* and *pax3* expression in embryos was examined by in situ hybridization as described in Methods.

‡Number and frequency of embryos with ectopic *slug* or *pax3* expression, of the total number with β -gal staining anywhere in the embryo. In the +dex group examined with *slug*, none showed ectopic expression in ventrolateral ectoderm not contiguous with the endogenous *slug* domain. In the +dex group examined with *pax3*, 55 (71%) embryos showed ectopic expression that was broad and contiguous with the endogenous *pax3* expression, 3 (4%) embryos showed ectopic expression in ventrolateral ectoderm that was non-contiguous with the endogenous *pax3* domain.

§Total number of embryos examined.

¶Number of independent experiments.




Fig. 12. *opl* induces ectopic *slug* and *pax3* and inhibits *XK81* expression in embryos. (A) Experimental scheme. Albino embryos were injected in one cell at the 2-cell stage with 500 pg *oplGR* or *oplΔC* plus 100 pg *lacZ* RNA as lineage tracer. Embryos were incubated in saline, or with addition of dexamethasone (dex) at stage 11, until embryos reached midneurula (stage 18), when they were harvested for in situ analysis. See Methods for details. (B-E) Ectopic *slug* (Mayor et al., 1995) and *pax3* (Espeseth et al., 1995) expression in whole embryos. Embryos were injected with *oplGR* plus *lacZ* RNAs and incubated without (B,D) or with dex (C,E) before histochemical staining for β -gal (light blue) and in situ hybridization for *slug* or *pax3* (purple). Anterior is to the top in all panels. Arrowheads indicate injected side. Ectopic expression of *slug* and *pax3* is indicated by brackets. (F,G) *oplΔC* suppressed expression of the epidermal cyokeratin *XK81* (Jonas et al., 1995). Embryos were injected with 500 pg *globin* (F) or *oplΔC* (G) RNAs mixed with 100 pg *lacZ* RNA, incubated in saline until stage 18, before histochemical staining for β -gal (light blue) and in situ hybridization for *XK81* (purple). Anterior is to the top in both panels. Endogenous *XK81* is expressed throughout the ventrolateral epidermis and excluded from the neural plate (white regions). White arrow indicates *oplΔC*-expressing cells (marked by β -gal staining) do not express *XK81*. A, anterior; P, posterior.

and dorsal neural tube markers and suppress ventral ectodermal (epidermal) fates. Embryos were injected with either *oplGR* or *oplΔC* RNA, along with *lacZ* RNA as lineage tracer. For *oplGR* injections, dexamethasone (dex) was added at stage 11 when response to *oplGR* was maximal as indicated in the aggregate formation assay (Table 2, and not shown). Neural crest formation was assayed by expression of *slug*, dorsal neural tube fates were assayed by expression of *pax3* and epidermal fate was assayed by expression of *XK81*.

Representative data is shown in Fig. 12B-E and the results collated in Table 3. Without dex, uniform *slug* expression was observed on both sides of the embryo (Fig. 12B). After dex treatment, concentration of *lacZ* lineage tracer was observed reflecting the cell aggregates previously seen in pigmented embryos (see Fig. 11). In dex-treated embryos, *slug* expression expanded anteriorly on the injected side of the embryo (Fig. 12C) in 42% of injected embryos. Similarly, a large expansion of the *pax3* expression domain was observed after dex addition in 75% of injected embryos. In a few cases (4% of injected embryos), patches of *pax3* expression were not connected to the neural plate.

We also asked whether *opl* altered expression of the ventral epidermal marker, *XK81*. Since epidermis is specified early, we used the constitutively active construct *oplΔC*. Embryos injected with *globin* RNA as a control (Fig. 12F) along with *lacZ* showed *XK81* expression over the entire ventral ectoderm, obscuring the β -gal staining. After injection of *oplΔC* (Fig. 12G), however, 51% of embryos showed large patches of *lacZ* expression since *XK81* is not expressed in these regions (Table 4). Regions of ventral ectoderm that did not express *XK81* always coincided with regions of *lacZ* expression.

In summary, in whole embryos, *opl* constructs were able to expand the expression domains of a neural crest and a dorsal neural tube marker, and was able to inhibit expression of an

Table 4. Frequency of XK81 inhibition in *opl* Δ C-injected embryos

Treatment*	<i>XK81</i> inhibition (%)†	Number of embryos‡	Number of experiments§
<i>opl</i> Δ C	43 (51)	84	3
<i>globin</i>	0 (0)	85	3

Embryos were prepared as described in Fig. 8A; *XK81* expression was scored by in situ hybridization on neurula (stage 18) embryos.

*One blastomere of 2-cell embryos was injected with *opl* Δ C or *globin* and embryos were incubated in saline until harvest. See Methods for details.

†Number and frequency of embryos with *XK81* expression inhibited when *opl* expression (marked by β -gal staining) was located in ventrolateral ectoderm.

‡Total number of embryos examined.

§Number of independent experiments.

epidermal cytochrome gene, which is a marker of the ventral ectoderm. The *slug* expression domain also expands in *Zic3*- and *Zic-r1*-injected embryos, consistent with these results.

DISCUSSION

We report isolation of *opl*, a gene similar to *Drosophila odd-paired* and a new member of the *Zic* gene family in *Xenopus*. *opl* expression indicates that neural determination begins by the onset of gastrulation, and the *opl* protein appears to have three activities. First, *opl* can sensitize the presumptive neuroectoderm for induction, suggesting that it may be a neural competence factor. Second, consistent with its later expression in the dorsal neural tube and neural crest, an activated form of *opl*, *opl* Δ C, can activate neural crest and dorsal neural tube markers. Third, *opl* can synergize with *noggin* to induce expression of engrailed. These data indicate that *opl* may be a key regulator of *Xenopus* neurogenesis.

opl expression defines an early neuroectodermal domain

opl is most similar to the mouse *Zic1* gene that is expressed in the embryonic mesoderm and presumptive neuroectoderm of mice (Nagai et al., 1997), with later expression persisting in the dorsal neural tube and the dorsomedial region of the somites. *Xenopus opl* is not expressed at significant levels in the mesoderm. However, the early expression of *Xenopus opl*, mouse *Zic1* and zebrafish *opl* (Grinblat et al., 1998) during neurogenesis, and their later restriction of expression to the dorsal neural tube suggests that their function may be conserved during vertebrate neural development.

At early gastrula, when *opl* is first expressed, neural tissue is not yet specified, as judged by isolation and culture of dorsal ectoderm and later analysis for markers of neural differentiation (Sive et al., 1989). However, restricted *opl* expression in dorsal ectoderm clearly shows that the neuroectoderm has begun to be set aside by the onset of gastrulation. A large part of the early expression domain of *opl* is in dorsal ectoderm not yet underlain by the involuting mesendoderm. This dorsal restriction of *opl* RNA is dependent on dorsal signals since it is abolished in UV-treated embryos (J. G. and H. S., unpublished data). These data indicate that *opl* RNA accumulation may be activated by planar signals from the




Fig. 13. Model of the roles *opl* plays in early neural determination. Schematics of whole embryos during gastrulation are shown (dorsal views, anterior is to the top). Arrow, dorsal lip of blastopore; A, anterior; P, posterior. High level *opl* expression (spots) is activated in the dorsal ectoderm by early gastrula. By midgastrula *opl* expression has sensitized dorsal ectodermal cells for later induction and patterning by neural inducers such as *noggin* (light stripes). *opl* also acts by suppressing ventral ectodermal fates, such as epidermis (T bar). By late gastrula, *opl* expression has become restricted to the presumptive dorsal neural tube and neural crest, where it activates expression of neural markers in these regions. A dorsally restricted synergizing activity (dark stripes) is necessary for activation of neural crest fates. See text for further discussion.

organizer, or by patterning signals present in the dorsal ectoderm prior to the onset of gastrulation (Sokol and Melton, 1991; Wylie et al., 1996). Recent reports concerning other *Xenopus Zic* family members (*Zic3* and *Zic-r1*) indicate that their expression requires removal of BMP signaling (Nakata et al., 1997; Mizuseki et al., 1998). Consistent with this, *opl* is induced by *noggin* (Kuo, J. S., Gamse, J. and Sive, H., unpublished data), however, it is not clear whether such signaling initiates *opl* expression, or is required for a later maintenance step.

opl can modulate neural competence

The early *opl* expression domain suggested that it may be a competence factor and, indeed, *opl* could increase the responsiveness of isolated ectoderm to *noggin* by 10-fold. Our data indicate that expression of *opl* may account for some of the enhanced sensitivity of the dorsal ectoderm to neural induction as noted by other investigators (Sharpe et al., 1987; Otte et al., 1991). The translation initiation factor *EIF4AII* has recently been shown to synergize with *noggin* to activate expression of some neural crest markers as well as markers of the neuroectoderm proper (Morgan and Sargent, 1997). *EIF4AII* is expressed considerably later than *opl*, by midgastrula, and may be a target of *opl* activation. Protein kinase C (PKC) activity has also been implicated in conferring neural competence on the dorsal ectoderm (Otte et al., 1991), while the *Notch* signaling pathway

may also be involved in directing neural competence (Coffman et al., 1993). It is unknown whether *opl* can modulate or be modulated by either of these pathways.

opl* can activate *engrailed

In conjunction with *noggin*, *opl* and *oplΔC* strongly potentiated expression of the posterior neural marker *engrailed*, expressed in the midbrain/hindbrain region. Although *opl* is expressed in presumptive posterior neurectoderm, we did not expect this result, since *opl* RNA is present throughout the anteroposterior extent of the future brain at early stages. It is possible, however, that *opl* protein activity is modulated along the A/P neural axis. One intriguing connection between the ability of *opl* to potentiate expression of *engrailed* and *Drosophila opa* is that *opa* is necessary for the correct temporal activation of *Drosophila wingless* (Benedyk et al., 1994), while, in *Xenopus*, the wingless homologs *wnt3A* and *wnt8* can posteriorize neurectoderm in combination with *noggin* (McGrew et al., 1995, 1997; Fredieu et al., 1997). This suggests that *opl* may activate *wnt* genes or act downstream of *wnt* proteins. Indeed the expression patterns of *opl* and *wnt3A* are very similar from late gastrula (Wolda et al., 1993). However, unlike *wnt3A*, *opl* expression did down-regulate anterior neurectodermal markers, suggesting that the activities of these proteins are not entirely equivalent.

***opl* as an activator of dorsal neural tube and neural crest fates**

The later expression of *opl* in the dorsal neural tube and neural crest correlated with the ability of a truncated form of *opl*, *oplΔC*, to activate genes characteristic of these fates. Like *opl*, the dorsal neural tube marker, *pax3*, is transiently expressed initially across the entire dorsoventral extent of both the *Xenopus* and chick neural plates and is later expressed solely in the future dorsal neural tube (Liem et al., 1995; Bang et al., 1997). However, *opl* is expressed earlier than *pax3*, consistent with a role for *opl* in activating *pax3*. As *pax3* expression increases in the future dorsal neural tube, *opl* expression also increases and later becomes dorsally restricted. The expression of *opl* in presumptive neural crest from late gastrula again precedes the expression of neural crest-specific markers in this region (Mayor et al., 1995), consistent with a role for *opl* in regulating neural crest formation. *opl* expression across both presumptive dorsal neural tube and neural crest regions at late gastrula suggests that these two neural domains are initially defined as a unit that later becomes subdivided into dorsal neural tube and neural crest subdomains. Since recent studies have shown that *wnt* proteins can also activate neural crest markers in neuralized ectoderm (Saint-Jeannet et al., 1997; Chang and Hemmati-Brivanolou, 1998), another connection between *opl* and *wnt* expression is possible.

***opl* activity is modulated by synergizing factors**

Several lines of evidence indicate that *opl* protein requires synergizing factors. First, *oplΔC*, but not full-length *opl* protein could activate dorsal neural tube and neural crest markers in animal caps. In other respects, *opl* appears to have similar, though weaker activity to *oplΔC*, as both constructs could repress ventral ectodermal markers, synergize with *noggin* and catalyse formation of pigmented aggregates. This suggests that *oplΔC* is an activated form of *opl*, although we cannot rule out

that *oplΔC* has a novel activity. Second, we showed that, in animal caps, intact *opl* in conjunction with *noggin* was able to activate a dorsal neural tube marker, but not neural crest markers. This suggests that factors induced by *noggin* modulate *opl* activity; however, since *opl* could not activate neural crest markers even in conjunction with *noggin*, some other factor may allow *opl* to activate neural crest-specific gene expression. Such a factor may act by de-repressing a carboxy terminus inhibitory function in the *opl* protein, perhaps by altering *opl* phosphorylation. Third, in whole embryos, activated *opl* constructs could expand the domain of *slug* and *pax3* expression but only adjacent to the normal expression domains of these genes, and never in the extreme anterior neural plate. This further suggests that *opl* activity requires cofactors that are present in the neural plate, neural crest and in early gastrula animal caps, but that are absent from or counteracted by inhibitors in the ventral ectoderm of older embryos.

These considerations raise the question of whether the activation of dorsal neural tube fates, the *engrailed*-inducing capacity and the competence-promoting activity of *opl* are distinct functions, perhaps requiring different domains of *opl* or different cofactors. In animal caps, *opl* in conjunction with *noggin* was able to promote expression of both dorsal and ventral neural tube markers, indicating that expression of ventral neural tube markers is not incompatible with *opl* activity. Thus *opl* may act by a similar mechanism throughout the neural plate, and may play a role in early gastrula to activate both dorsal and ventral neural tube markers. Since, by the end of gastrulation, *opl* is not expressed ventrally, ventral *opl* activity is only transient.

Unlike *opl*, two related genes, *Zic3* and *Zic-r1* are able to activate both general neuronal markers and a neural crest marker in animal caps without requiring *noggin* addition (Nakata et al., 1997; Mizuseki et al., 1998). The differences in our results may reflect a difference in assay conditions that were employed, or may indicate different activities for these related genes. Since the neuronal markers that were examined in these studies are expressed in restricted areas of the neural plate, whereas expression of *Zic3* and *Zic-r1* is much broader, activity of these genes may also be modulated by cofactors. Similarly, *Zic3* and *Zic-r1* increased *slug* expression only adjacent to the normal *slug* expression domain and could not induce it in ventral ectoderm.

***opl* modulates cell adhesion**

One of the most striking phenotypes consistently produced by *opl* and also produced by *Zic3* (Nakata et al., 1997), was the appearance of cellular aggregates in the ventrolateral ectoderm, but not within the neural plate itself. Aggregates did not express neural or neural crest markers unless they directly contacted the neural plate. In both whole embryos and in animal caps injected with *opl* RNA, aggregates comprised cells that were loosely adherent (not shown). In both the whole embryo and the animal cap, the cells appeared healthy, surviving and dividing after disaggregation in the culture dish. One intriguing hypothesis is that *opl* suppresses an adhesion pathway responsible for ectodermal-epithelial integrity that is normally down-regulated as neural crest fates are determined (Bronner-Fraser, 1995). Since *opl* did not induce ectopic slug in the ventral ectoderm, but did induce aggregates there, the

aggregates are clearly not committed neural crest cells, but may represent some early step in neural crest commitment. Consistent with this hypothesis, *opl* is expressed sequentially in the cranial neural crest segments just before the cells mound up, lose adhesivity and begin migrating (Sadaghiani and Thiebaud, 1987).

opl and inhibition of epidermal fates

In *Xenopus*, formation of ventral fates including epidermis appears to be dependent on Bone Morphogenetic Protein (BMP) activity (Wilson and Hemmati-Brivanlou, 1995). Suppression of this activity by *noggin* and *chordin* proteins during gastrulation results in neural determination (Piccolo et al., 1996; Zimmerman et al., 1996). In whole embryos, *opl* can inhibit expression of the epidermal cytokeratin gene *XK81* while, in animal caps, *opl* also suppresses expression of *GATA2*, a ventral ectodermal marker that is regulated by BMP4 signaling. Since this suppression is not correlated with an ability of *opl* or *opl* Δ C alone to activate general neural markers, *opl* is able to inhibit only part of the dorsoventral ectodermal patterning pathway. In accord with this, *opl* expression overlaps that of BMP4, until midgastrula when BMP4 RNA begins to be cleared from the presumptive neural plate (J. G. and H. S., unpublished).

A model for *opl* function

Our data suggest a model for the role of *opl* in early neural determination (Fig. 13). Early during gastrulation, *opl* gene expression is induced, either by planar signals from the organizer or by pre-existing signals within the dorsal ectoderm. The early expression domain of *opl* throughout the neural plate sensitizes the neuroectoderm for subsequent neuralizing signals, such as *noggin* and *chordin*, derived from the organizer. This sensitization both modulates general neural readout and is also involved in activating relatively posterior neural markers, such as *engrailed*. By the end of gastrulation, *opl* expression in the dorsal neural plate and presumptive neural crest directs fates characteristic of these regions. The activity of *opl* in the presumptive neural crest is modulated by a regulatory domain in the carboxy terminus, suggesting that a laterally, but not anteriorly, localized factor(s) may control *opl* activity. The ability of *opl* to suppress cell adhesion may be part of the commitment program for neural crest fates.

Future challenges are to analyse the consequence of *opl* ablation, to isolate the downstream direct targets of *opl*, and to further understand how *opl* fits into the hierarchy of neural regulatory genes.

We thank Igor Dawid, Richard Harland, Paul Krieg, Nancy Papalopulu, Michael Sargent, Dave Turner and Andrea Vortkamp for kind gifts of plasmids. We thank W. David Willison for help with the subtractive screen, Cathy Nocente-McGrath for the midgastrula λ Zap phage library, Melissa Ronces for helping isolate the full-length *opl* cDNA, Harvey Lodish for tissue culture reagents and facilities, Liuda Ziaugra for expert DNA sequencing, and Jeanne Reis for histological expertise. We greatly appreciate the helpful comments and discussions with members of the Sive laboratory during the interminably long course of this work, and thank Andrew Lassar for criticism of the manuscript. We also thank Jun Aruga for interesting discussion concerning *Xenopus Zic3* experiments. This work was supported by grants from the NSF and NIH to H. L. S. We appreciate support from Genetics Institute, Cambridge MA. J. S. K. was the recipient of a

Medical Scientist Training Program Fellowship (PHS grant 2-T32-GM07753) from the Harvard MD-PhD Program. M. P. was the recipient of a fellowship from the Human Frontiers Science Program. X.L. was the recipient of an NIH postdoctoral fellowship. H. L. S. was the recipient of a NSF Young Investigators Award and the Latham Family Development Professorship at MIT.

REFERENCES

- Aruffo, A. and Seed, B. (1987). Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. *Proc. Natl Acad. Sci. USA* **84**, 8573-8577.
- Aruga, J., Nagai, T., Tokuyama, T., Hayashizaki, Y., Okazaki, Y., Chapman, V. M. and Mikoshiba, K. (1996). The mouse *zic* gene family. Homologues of the *Drosophila* pair-rule gene *odd-paired*. *J. Biol. Chem.* **271**, 1043-7.
- Aruga, J., Yokota, N., Hashimoto, M., Furuichi, T., Fukuda, M. and Mikoshiba, K. (1994). A novel zinc finger protein, *zic*, is involved in neurogenesis, especially in the cell lineage of cerebellar granule cells. *J. Neurochem.* **63**, 1880-90.
- Bang, A., Papalopulu, N., Kintner, C. and Goulding, M. (1997). Expression of *Pax-3* is initiated in the early neural plate by posteriorizing signals produced by the organizer and by posterior non-axial mesoderm. *Development* **124**, 2075-2085.
- Benedyk, M., Mullen, J. and DiNardo, S. (1994). *odd-paired*: a zinc finger pair-rule protein required for the timely activation of *engrailed* and *wingless* in *Drosophila* embryos. *Genes Dev.* **8**, 105-117.
- Blitz, I. L. and Cho, K. W. Y. (1995). Anterior neuroectoderm is progressively induced during gastrulation: the role of the *Xenopus* homeobox gene *orthodenticle*. *Development* **121**, 993-1004.
- Bradley, L., Snape, A., Bhatt, S. and Wilkinson, D. (1993). The structure and expression of the *Xenopus* *Krox-20* gene: conserved and divergent patterns of expression in rhombomeres and neural crest. *Mech. Dev.* **40**, 73-84.
- Bronner-Fraser, M. (1995). Patterning of the vertebrate neural crest. *Perspectives on Developmental Neurobiology* **3**, 53-62.
- Chang, C. and Hemmati-Brivanlou, A. (1998). Neural crest induction by *Xwnt7B* in *Xenopus*. *Dev. Biol.* **194**, 129-134.
- Coffman, C. R., Skoglund, P., Harris, W. A. and Kintner, C. R. (1993). Expression of an extracellular deletion of *Xotch* diverts cell fate in *Xenopus* embryos. *Cell* **73**, 659-671.
- Condie, B. G. and Harland, R. M. (1987). Posterior expression of a homeobox gene in early *Xenopus* embryos. *Development* **101**, 93-105.
- Ekker, S. C., McGrew, L. L., Lai, C.-J., Lee, J. J., von Kessler, D. P., Moon, R. T. and Beachy, P. A. (1995). Distinct expression and shared activities of members of the *hedgehog* gene family of *Xenopus laevis*. *Development* **121**, 2337-2347.
- Espeseth, A., Johnson, E. and Kintner, C. (1995). *Xenopus* F-cadherin, a novel member of the cadherin family of cell adhesion molecules, is expressed at boundaries in the neural tube. *Mol. Cell Neurosci.* **6**, 199-211.
- Eyal-Giladi, H. (1954). Dynamic aspects of neural induction in amphibia. *Arch. Biologie* **65**, 179-259.
- Fredieu, J., Cui, Y., Maier, D., Danilchik, M. and Christian, J. (1997). *Xwnt-8* and lithium can act upon either dorsal mesodermal or neuroectodermal cells to cause a loss of forebrain in *Xenopus* embryos. *Dev. Biol.* **186**, 100-114.
- Gammill, L. and Sive, H. (1997). Identification of *otx2* target genes and restrictions in ectodermal competence during *Xenopus* cement gland formation. *Development* **124**, 471-481.
- Grinblat, Y., Gamse, J., Patel, M. and Sive, H. (1998). Determination of the zebrafish forebrain: induction and patterning. *Development* in press.
- Harland, R. M. (1991). In situ hybridization: an improved whole-mount method for *Xenopus* embryos. *Methods in Cell Biology* **36**, 685-695.
- Harris, W. and Hartenstein, V. (1991). Neuronal determination without cell division in *Xenopus* embryos. *Neuron* **6**, 499-515.
- Hemmati-Brivanlou, A. and Harland, R. (1989). Expression of an *engrailed*-related protein in the anterior neural ectoderm of early *Xenopus* embryos. *Development* **106**, 611-617.
- Hemmati-Brivanlou, A. and Melton, D. A. (1994a). Inhibition of activin receptor signaling promotes neuralization in *Xenopus*. *Cell* **77**, 273-281.
- Hollenberg, S. M., Cheng, P. F. and Weintraub, H. (1993). Use of a

- conditional MyoD transcription factor in studies of MyoD trans-activation and muscle determination. *Proc. Natl. Acad. Sci. USA* **90**, 8028-8032.
- Hopwood, N. D., Pluck, A. and Gurdon, J. B.** (1989). A *Xenopus* mRNA related to *Drosophila twist* is expressed in response to induction in the mesoderm and the neural crest. *Cell* **59**, 893-903.
- Jonas, E., Sargent, T. D. and Dawid, I. B.** (1985). Epidermal keratin gene expressed in embryos of *Xenopus laevis*. *Proc. Nat. Acad. Sci. USA* **82**, 5413-5417.
- Jones, E. A. and Woodland, H. R.** (1987). The development of animal cap cells in *Xenopus*: a measure of the start of animal cap competence to form mesoderm. *Development* **101**, 557-563.
- Knecht, A. K. and Harland, R. M.** (1997). Mechanisms of dorsal-ventral patterning in noggin-induced neural tissue. *Development* **124**, 2477-2488.
- Kintner, C. R. and Dodd, J.** (1991). Hensen's node induces neural tissue in *Xenopus* ectoderm. Implications for the action of the organizer in neural development. *Development* **113**, 1495-1505.
- Kintner, C. R. and Melton, D. A.** (1987). Expression of *Xenopus* N-CAM RNA in ectoderm in an early response of neural induction. *Development* **99**, 311-325.
- Kolm, P. and Sive, H.** (1995a). Regulation of the *Xenopus* labial homeodomain genes, HoxA1 and HoxD1: activation by retinoids and peptide growth factors. *Dev. Biol.* **167**, 34-49.
- Kolm, P. and Sive, H.** (1995b). Efficient hormone-inducible protein function in *Xenopus laevis*. *Dev. Biol.* **171**, 267-272.
- Kolm, P. and Sive, H. L.** (1997). Retinoids and posterior neural induction: A reevaluation of Nieuwkoop's two-step hypothesis. in *Cold Spring Harbor Symposia on Quantitative Biology LXII* (Cold Spring Harbor Laboratory Press., Cold Spring Harbor, NY), in press.
- Kozak, M.** (1987). An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. *Nuc. Acids. Res* **15**, 8125-8148.
- Krieg, P. A. and Melton, D. A.** (1984). Functional messenger RNAs are produced by SP6 *in vitro* transcription of cloned cDNAs. *Nuc. Acids Res.* **12**, 7057-7070.
- Krieg, P. A., Varnum, S. M., Wormington, W. M. and Melton, D. A.** (1989). The mRNA Encoding Elongation Factor 1- α (EF-1 α) Is a Major Transcript at the Midblastula Transition in *Xenopus*. *Dev. Biol.* **133**, 93-100.
- Kuo, J. S., Veale, R., Maxwell, B. and Sive, H.** (1996). Translational inhibition by 5' polycytidine tracts in *Xenopus* embryos and *in vitro*. *Gene* **176**, 17-21.
- Lamb, T. M., Knecht, A. K., Smith, W. C., Stachel, S. E., Economides, A. N., Stahl, N., Yancopolous, G. D. and Harland, R. M.** (1993). Neural induction by the secreted polypeptide noggin. *Science* **262**, 713-718.
- Liem, K., Jr., Tremml, G., Roelink, H. and Jessell, T. M.** (1995). Dorsal differentiation of neural plate cells induced by BMP-mediated signals from epidermal ectoderm. *Cell* **82**, 969-79.
- Ma, Q., Kintner, C. and Anderson, D.** (1996). Identification of *neurogenin*, a vertebrate neuronal determination gene. *Cell* **87**, 43-52.
- Mattioni, T., Louvion, J. and Picard, D.** (1994). Regulation of protein activities by fusion to steroid binding domains. In *Methods Cell Biol.* (ed. M. Roth). Academic Press: San Diego.
- Mayor, R., Morgan, R. and Sargent, M.** (1995). Induction of the prospective neural crest of *Xenopus*. *Development* **121**, 767-777.
- McGrew, L., Hoppler, S. and Moon, R.** (1997). Wnt and FGF pathways cooperatively pattern anteroposterior neural ectoderm in *Xenopus*. *Mech. Dev.* **69**, 105-114.
- McGrew, L., Lai, C. and Moon, R.** (1995). Specification of the anteroposterior neural axis through synergistic interaction of the Wnt signaling cascade with *noggin* and *folliculin*. *Dev. Biol.* **172**, 337-342.
- Mizuseki, K., Kishi, M., Matsui, M., Nakanishi, S. and Sasai, Y.** (1998). *Xenopus* Zic-related-1 and Sox-2, two factors induced by chordin, have distinct activities in the initiation of neural induction. *Development* **125**, 579-587.
- Mohun, T., Brennan, S., Dathan, N., Fairman, S. and Gurdon, J. B.** (1984). Cell type-specific activation of actin genes in the early amphibian embryo. *Nature* **511**, 716-721.
- Morgan, R. and Sargent, M. G.** (1997). The role in neural patterning of translation initiation factor eIF4AII; induction of neural fold genes. *Development* **124**, 2751-2760.
- Nagai, T., Aruga, J., Takada, S., Gunther, T., Sporle, R., Schughart, K. and Mikoshiba, K.** (1997). The expression of the mouse Zic1, Zic2, and Zic3 gene suggests an essential role for Zic genes in body pattern formation. *Dev. Biol.* **182**, 299-313.
- Nakata, K., Nagai, T., Aruga, J. and Mikoshiba, K.** (1997). *Xenopus* Zic3, a primary regulator both in neural and neural crest development. *Proc. Natl. Acad. Sci. USA* **94**, 11980-11985.
- Nieuwkoop, P. and Koster, K.** (1995). Vertical versus planar induction in amphibian early development. *Dev., Growth Differ.* **37**, 653-668.
- Nieuwkoop, P. and Faber, J.** (1967). *Normal Table of Xenopus laevis (Daudin)*. Amsterdam: North-Holland Publishing Co.
- Otte, A., Kramer, I. and Durston, A.** (1991). Protein kinase C and regulation of the local competence of *Xenopus* ectoderm. *Science* **251**, 570-573.
- Pannese, M., Polo, C., Andreazzoli, M., Vignali, R., Kablar, B., Barsacchi, G. and Boncinelli, E.** (1995). The *Xenopus* homologue of *Otx2* is a maternal homeobox gene that demarcates and specifies anterior body regions. *Development* **121**, 707-720.
- Patel, M. and Sive, H. L.** (1996). PCR-based subtractive cDNA cloning. In *Current Protocols in Molecular Biology* (ed. F. Ausubel et al.). New York: John Wiley and Sons, Inc.
- Piccolo, S., Sasai, Y., Lu, B. and De Robertis, E. M.** (1996). Dorsoventral patterning in *Xenopus*: inhibition of ventral signals by direct binding of chordin to BMP-4. *Cell* **86**, 589-598.
- Placzek, M. and Furley, A.** (1996). Neural development: Patterning cascades in the neural tube. *Curr. Biol.* **6**, 526-529.
- Roelink, H., Augsburger, A., Heemskerk, J., Korzh, V., Norlin, S., Ruiz-i-Altaba, A., Tanabe, Y., Placzek, M., Edlund, T., Jessell, T. and Dodd, J.** (1994). Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of hedgehog expressed by the notochord. *Cell* **76**, 761-775.
- Ruiz i Altaba, A., Jessell, T. M. and Roelink, H.** (1995). Restrictions to floor plate induction by hedgehog and winged-helix genes in the neural tube of frog embryos. *Mol. Cell Neurosci.* **6**, 106-21.
- Rupp, R., Snider, L. and Weintraub, H.** (1994). *Xenopus* embryos regulate the nuclear localization of XMyoD. *Genes Dev.* **8**, 1311-1323.
- Ruppert, J. M., Kinzler, K. W., Wong, A. J., Bigner, S. H., Kao, F. T., Lax, M. L., Seunanez, H. N., O'Brien, S. J. and Vogelstein, B.** (1988). The GLI-kruppel family of human genes. *Mol. Cell Biol.* **8**, 3104-3113.
- Sadaghiani, B. and Thiebaud, C. H.** (1987). Neural Crest Development in the *Xenopus laevis* Embryo, Studied by Interspecific Transplantation and Scanning Electron Microscopy. *Dev. Biol.* **124**, 91-110.
- Sagerström, C., Grinblat, Y. and Sive, H.** (1996). Anteroposterior patterning in the zebrafish, *Danio rerio*: an explant assay reveals inductive and suppressive cell interactions. *Development* **122**, 1873-1883.
- Sagerström, C., Sun, B. and Sive, H. L.** (1997). Subtractive cDNA cloning. *Ann. Rev. Biochem.* **66**, 751-783.
- Saha, M., Miles, R. and Grainger, R.** (1997). Dorso-ventral patterning during neural induction in *Xenopus*: assessment of spinal cord regionalization with HB9, a marker for the motor neuron region. *Dev. Biol.* **187**, 209-223.
- Saha, M. S., Michel, R. B., Gulding, K. M. and Grainger, R. M.** (1993). A *Xenopus* homeobox gene defines dorsal-ventral domains in the developing brain. *Development* **118**, 193-202.
- Saint-Jeannet, J., He, X., Varmus, H. and Dawid, I.** (1997). Regulation of dorsal fate in the neuraxis by Wnt-1 and Wnt-3a. *Proc. Natl Acad. Sci. USA* **94**, 13713-13718.
- Sambrook, J., Fritsch, E. and Maniatis, T.** (1989). *Molecular Cloning: A Laboratory Manual*. Plainview, NY: Cold Spring Harbor Laboratory Press.
- Sasai, Y. and DeRobertis, E.** (1997). Ectodermal patterning in vertebrate embryos. *Dev. Biol.* **182**, 5-20.
- Savage, R. and Phillips, C. R.** (1989). Signals from the dorsal blastopore lip region during gastrulation bias the ectoderm toward a nonepidermal pathway of differentiation in *Xenopus laevis*. *Dev. Biol.* **133**, 157-168.
- Servetnick, M. and Grainger, R. M.** (1991). Changes in neural and lens competence in *Xenopus* ectoderm: evidence for an autonomous developmental timer. *Development* **112**, 177-188.
- Sharpe, C., Fritz, A., DeRobertis, E. and Gurdon, J.** (1987). A homeobox-containing marker of posterior neural differentiation show the importance of predetermination in neural induction. *Cell* **50**, 749-758.
- Sharpe, C. and Gurdon, J.** (1990). The induction of anterior and posterior neural genes in *Xenopus laevis*. *Development* **109**, 765-774.
- Sive, H., Hattori, K. and Weintraub, H.** (1989). Progressive determination during formation of the anteroposterior axis in *Xenopus laevis*. *Cell* **58**, 171-180.
- Sive, H. L. and Cheng, P. F.** (1991). Retinoic acid perturbs the expression of *Xhox.lab* genes and alters mesodermal determination in *Xenopus laevis*. *Genes Dev.* **5**, 1321-1332.
- Smith, W. and Harland, R.** (1992). Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in *Xenopus* embryos. *Cell* **70**, 829-840.

- Sokol, S. and Melton, D. A.** (1991). Pre-existent pattern in *Xenopus* animal pole cells revealed by induction with activin. *Nature* **351**, 409-411.
- Stutz, F. and Spohr, G.** (1986). Isolation and characterization of sarcomeric actin genes expressed in *Xenopus laevis* embryos. *J. Mol. Biol.* **187**, 349-361.
- Turner, D. L. and Weintraub, H.** (1994). Expression of achaete-scute homolog 3 in *Xenopus* embryos converts ectodermal cells to a neural fate. *Genes Dev.* **8**, 1434-1447.
- Vortkamp, A., Gessler, M. and Grzeschik, K. H.** (1995). Identification of optimized target sequences for the Gli3 zinc finger protein. *DNA Cell Biol.* **14**, 629-634.
- Walmsley, M., Guille, M., Bertwistle, D., Smith, J., Pizzey, J. and Patient, R.** (1994). Negative control of *Xenopus* GATA-2 by activin and noggin with eventual expression in precursors of the ventral blood islands. *Development* **120**, 2519-2529.
- Wang, Z. and Brown, D. D.** (1991). A gene expression screen. *Proc Natl. Acad. Sci. USA* **88**, 11505-11509.
- Wilson, P. A. and Hemmati-Brivanlou, A.** (1995). Induction of epidermis and inhibition of neural fate by Bmp-4. *Nature* **376**, 331-333.
- Wolda, S., Moody, C. and Moon, R.** (1993). Overlapping expression of *Xwnt-3A* and *Xwnt-1* in neural tissue of *Xenopus laevis* embryos. *Dev. Biol.* **155**, 46-57.
- Wright, C. V. E., Morita, E. A., Wilkin, D. J. and De Robertis, E. M.** (1990). The *Xenopus* XIHbox 6 homeo protein, a marker of posterior neural induction, is expressed in proliferating neurons. *Development* **109**, 229-234.
- Wylie, C., Kofron, M., Payne, C., Anderson, R., Hosobuchi, M., Joseph, E. and Heasman, J.** (1996). Maternal beta-catenin establishes a 'dorsal signal' in early *Xenopus* embryos. *Development* **122**, 2987-2996.
- Yokota, N., Aruga, J., Takai, S., Yamada, K., Hamazaki, M., Iwase, T., Sugimura, H. and Mikoshiba, K.** (1996). Predominant expression of human *zic* in cerebellar granule cell lineage and medulloblastoma. *Cancer Res.* **56**, 377-83.
- Zimmerman, K., Shih, J., Bars, J., Collazo, A. and Anderson, D. J.** (1993). *XASH-3*, a novel *Xenopus* *achaete-scute* homolog, provides an early marker of planar neural induction and position along the mediolateral axis of the neural plate. *Development* **119**, 221-232.
- Zimmerman, L. B., De Jesus-Escobar, J. M. and Harland, R. M.** (1996). The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. *Cell* **86**, 599-606.